Subgroup analysis by Ki-67 and primary tumour origins of the randomized, placebo-controlled phase III study of surufatinib in advanced well-differentiated extrapancreatic neuroendocrine tumours (SANET-ep)

被引：1
|
作者：
Zhou, Z. [1 ]
Xu, J. [2 ]
Shen, L. [3 ]
Li, J. [16 ]
Bai, C. [4 ]
Chi, Y. [5 ,6 ]
Li, Z. [7 ]
Xu, N. [8 ]
Jia, R. [2 ]
Li, E. [9 ]
Liu, T. [10 ]
Bai, Y. [11 ]
Yuan, Y. [12 ]
Li, X. [13 ]
Wang, X. [14 ]
Chen, J. [15 ]
Wang, W. [1 ]
Li, J. [16 ]
He, J. [16 ]
Su, W. [16 ]
机构：
[1] Sun Yat Sen Univ, Ctr Canc, Dept Gastr & Pancreat Surg, Guangzhou, Guangdong, Peoples R China
[2] Chinese Peoples Liberat Army Gen Hosp, Dept Gastrointestinal Oncol, Med Ctr 5, Beijing, Peoples R China
[3] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ, Dept Gastrointestinal Oncol, Beijing, Peoples R China
[4] Peking Union Med Coll Hosp, Dept Oncol, Beijing, Peoples R China
[5] Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, Beijing, Peoples R China
[6] Peking Union Med Coll, Beijing, Peoples R China
[7] Sichuan Univ, West China Hosp, Dept Abdominal Oncol, Chengdu, Sichuan, Peoples R China
[8] Zhejiang Univ, Affiliated Hosp 1, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China
[9] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Med Oncol, Xian, Shaanxi, Peoples R China
[10] Fudan Univ, Zhongshan Hosp, Dept Oncol, Shanghai, Peoples R China
[11] Harbin Med Univ Canc Hosp, Dept Gastrointestinal Oncol, Harbin, Heilongjiang, Peoples R China
[12] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China
[13] Zhengzhou Univ, Affiliated Hosp 1, Dept Med Oncol, Zhengzhou, Henan, Peoples R China
[14] Shandong Univ, Qilu Hosp, Dept Med Oncol, Jinan, Shandong, Peoples R China
[15] Jiangsu Canc Hosp, Dept Oncol, Nanjing, Jiangsu, Peoples R China
[16] Hutchison MediPharma Ltd, Clin Dept & Regulatory Affairs, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1378
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1165P
引用
收藏
页码：S775 / S775
页数：1
相关论文
共 13 条
  • [1] Subgroup Analysis by Ki-67 and Primary Tumor Origins of the Randomized, Placebo-Controlled Phase 3 Study of Surufatinib in Advanced Well-Differentiated Extrapancreatic Neuroendocrine Tumors (SANET-ep)
    Zhou, Zhiwei
    Xu, Jianming
    Shen, Lin
    Li, Jie
    Bai, Chunmei
    Chi, Yihebali
    Li, Zhiping
    Xu, Nong
    Li, Enxiao
    Liu, Tianshu
    Bai, Yuxian
    Yuan, Ying
    Li, Xingya
    Wang, Xiuwen
    Chen, Jia
    Wang, Wei
    Guan, Sha
    Fan, Songhua
    Su, Weiguo
    PANCREAS, 2022, 51 (03) : E43 - E43
  • [2] Subgroup analysis by Ki-67 and baseline CgA of the randomized, placebo-controlled phase 3 study of surufatinib in advanced well-differentiated pancreatic neuroendocrine tumors (SANET-p).
    Yu, Xianjun
    Xu, Jianming
    Shen, Lin
    Bai, Chunmei
    Li, Jie
    Zhou, Zhiwei
    Li, Zhiping
    Li, Enxiao
    Yuan, Xianglin
    Chi, Yihebali
    Yin, Yongmei
    Lou, Wenhui
    Xu, Nong
    Bai, Yuxian
    Zhang, Tao
    Xiu, Dianrong
    Wang, Xiuwen
    Guan, Sha
    Xu, Qian
    Su, Weiguo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study
    Xu, Jianming
    Shen, Lin
    Zhou, Zhiwei
    Li, Jie
    Bai, Chunmei
    Chi, Yihebali
    Li, Zhiping
    Xu, Nong
    Li, Enxiao
    Liu, Tianshu
    Bai, Yuxian
    Yuan, Ying
    Li, Xingya
    Wang, Xiuwen
    Chen, Jia
    Ying, Jieer
    Yu, Xianjun
    Qin, Shukui
    Yuan, Xianglin
    Zhang, Tao
    Deng, Yanhong
    Xiu, Dianrong
    Cheng, Ying
    Tao, Min
    Jia, Ru
    Wang, Wei
    Li, Jing
    Fan, Songhua
    Peng, Mengye
    Su, Weiguo
    LANCET ONCOLOGY, 2020, 21 (11): : 1500 - 1512
  • [4] Efficacy and safety of surufatinib in patients with well-differentiated advanced extrapancreatic neuroendocrine tumors (NETs): Results from the randomized phase III study (SANET-ep)
    Xu, J.
    Shen, L.
    Zhou, Z.
    Li, J.
    Bai, C.
    Chi, Y.
    Li, Z.
    Xu, N.
    Jia, R.
    Li, E.
    Liu, T.
    Bai, Y.
    Yuan, Y.
    Li, X.
    Wang, X.
    Chen, J.
    Ying, J.
    Li, J.
    Fan, S.
    Su, W.
    ANNALS OF ONCOLOGY, 2019, 30 : 911 - 911
  • [5] Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep)
    Li, Jiarui
    Cheng, Yuejuan
    Bai, Chunmei
    Xu, Jianming
    Shen, Lin
    Li, Jie
    Zhou, Zhiwei
    Li, Zhiping
    Chi, Yihebali
    Yu, Xianjun
    Li, Enxiao
    Xu, Nong
    Liu, Tianshu
    Lou, Wenhui
    Bai, Yuxian
    Yuan, Xianglin
    Wang, Xiuwen
    Yuan, Ying
    Chen, Jia
    Guan, Sha
    Fan, Songhua
    Su, Weiguo
    EUROPEAN JOURNAL OF CANCER, 2022, 169 : 1 - 9
  • [6] Health-related quality-of-life results from SANET-ep: A phase III study of surufatinib versus placebo for advanced extrapancreatic neuroendocrine tumors.
    Bai, Chunmei
    Xu, Jianming
    Shen, Lin
    Li, Jie
    Zhou, Zhiwei
    Chi, Yihebali
    Li, Zhiping
    Xu, Nong
    Li, Enxiao
    Liu, Tianshu
    Bai, Yuxian
    Yuan, Ying
    Li, Xingya
    Wang, Xiuwen
    Chen, Jia
    Ying, Jieer
    Li, Jing
    Fan, Songhua
    Peng, Mengye
    Su, Weiguo
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] 'Health-related quality of life in patients with advanced well-differentiated pancreatic and extra pancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double- blind, phase III trials (SANET-p and SANET-ep)' (vol 169, pg 1, 2022)
    Li, Jiarui
    Cheng, Yuejuan
    Bai, Chunmei
    Xu, Jianming
    Shen, Lin
    Li, Jie
    Zhou, Zhiwei
    Li, Zhiping
    Chi, Yihebali
    Yu, Xianjun
    Li, Enxiao
    Xu, Nong
    Liu, Tianshu
    Lou, Wenhui
    Bai, Yuxian
    Yuan, Xianglin
    Wang, Xiuwen
    Yuan, Ying
    Chen, Jia
    Guan, Sha
    Fan, Songhua
    Su, Weiguo
    EUROPEAN JOURNAL OF CANCER, 2023, 178 : 247 - 248
  • [8] Surufatinib (S) for patients (Pts) with advanced pancreatic neuroendocrine tumours (SANET-p): A randomized, double-blind, placebo (P)-controlled phase III trial (NCT02589821)
    Xu, J.
    Shen, L.
    Bai, C.
    Li, J.
    Zhou, Z.
    Yu, X.
    Li, Z.
    Li, E.
    Yuan, X.
    Chi, Y.
    Yin, Y.
    Lou, W.
    Xu, N.
    Bai, Y.
    Zhang, T.
    Xiu, D.
    Wang, X.
    Li, J.
    Fan, S.
    Su, W.
    ANNALS OF ONCOLOGY, 2020, 31 : S770 - S770
  • [9] Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
    Pavel, Marianne E.
    Singh, Simron
    Strosberg, Jonathan R.
    Bubuteishvili-Pacaud, Lida
    Degtyarev, Evgeny
    Neary, Maureen P.
    Carnaghi, Carlo
    Tomasek, Jiri
    Wolin, Edward
    Raderer, Markus
    Lahner, Harald
    Valle, Juan W.
    Pommier, Rodney
    Van Cutsem, Eric
    Tesselaar, Margot E. T.
    Delle Fave, Gianfranco
    Buzzoni, Roberto
    Hunger, Matthias
    Eriksson, Jennifer
    Cella, David
    Ricci, Jean-Francois
    Fazio, Nicola
    Kulke, Matthew H.
    Yao, James C.
    LANCET ONCOLOGY, 2017, 18 (10): : 1411 - 1422
  • [10] Design of a Phase 2, Prospective, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Lanreotide Depot 120 mg in Patients With Well Differentiated, Advanced Lung, or Thymus Neuroendocrine Tumors (NETs)
    Reidy-Lagunes, Diane
    Wolin, Edward M.
    Pitman-Lowenthal, Susan
    Cox, David
    Kulke, Matthew H.
    PANCREAS, 2016, 45 (03) : 480 - 481
12